Combinatorial de novo design and application of a biomimetic affinity ligand for the purification of human anti-HIV mAb 4E10 from transgenic tobacco

Journal of Molecular Recognition

Volumn 22, Issue 6, 2009, Pages 415-424

  Platis, Dimitris ^a   Maltezos, Anastasios ^a   Ma, Julian K C ^b   Labrou, Nikolaos E ^a  

^a AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Affinity chromatography; Aqueous two phase system; Biomimetic ligand; HIV; Molecular farming; Monoclonal antibody 4E10; Transgenic plants

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EPITOPE; LIGAND; MONOCLONAL ANTIBODY;

ADSORPTION; AMINO ACID SEQUENCE; ARTICLE; BIOMIMETICS; CHEMISTRY; COMBINATORIAL CHEMISTRY; ESCHERICHIA COLI; GENETICS; HUMAN; KINETICS; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; TOBACCO; TRANSGENIC PLANT;

ADSORPTION; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; BIOMIMETICS; COMBINATORIAL CHEMISTRY TECHNIQUES; EPITOPES; ESCHERICHIA COLI; HUMANS; KINETICS; LIGANDS; MOLECULAR SEQUENCE DATA; PLANTS, GENETICALLY MODIFIED; SEQUENCE HOMOLOGY, AMINO ACID; TOBACCO;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS; NICOTIANA TABACUM;

EID: 70349904561     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.954     Document Type: Article

References (69)

1. Abagyan RA, Totrov MM, Kuznetsov DA. 1994. ICM: a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 5: 488-506.
2. Aldridge S. 2006. Bioprocessing: downstream processing needs a boost. Genet. Eng. News 26: 51.
3. Bak H, Thomas OR. 2007. Evaluation of commercial chromatographic adsorbents for the direct capture of polyclonal rabbit antibodies from clarified antiserum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848: 116-130.
4. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78: 13232-13252. (Pubitemid 39507829)
5. Boschetti E. 2001. The use of thiophilic chromatography for antibody purification: a review. J. Biochem. Biophys. Methods 49: 361-389.
6. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
7. Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA. 2007. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J. Mol. Biol. 365: 1533-1544.
8. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion- associated motif in gp41. Immunity 22: 163-173.
9. Carter-Franklin JN, Victa C, McDonald P, Fahrner R. 2007. Fragments of protein A eluted during protein A affinity chromatography. J. Chromatogr. A 1163: 105-111.
10. Chu L, Robinson DK. 2001. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12: 180-187.
11. Clonis YD. 2006. Affinity chromatography matures as bioinformatic and combinatorial tools develop. J. Chromatogr. A 1101: 1-24.
12. Clonis YD, Labrou NE, Kotsira VP, Mazitsos C, Melissis S, Gogolas G. 2000. Biomimetic dyes as affinity chromatography tools in enzyme puri- fication. J. Chromatogr. A 891: 33-44.
13. Dalakouras T, Smith BJ, Platis D, Cox MM, Labrou NE. 2006. Development of recombinant protein-based influenza vaccine. Expression and affinity purification of H1N1 influenza virus neuraminidase. J. Chromatogr. A 1136: 48-56.
14. Evangelista RL, Kusnadi AR, Howard JA, Nikolov ZL. 1998. Process and economic evaluation of the extraction and purification of recombinant beta-glucuronidase from transgenic corn. Biotechnol. Prog. 14: 607-614.
15. Fahrner RL, Knudsen HL, Basey CD, Galan W, Feuerhelm D, Vanderlaan M, Blank GS. 2001. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 18: 301-327.
16. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. 2003. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17: 301-309.
17. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. 2004. Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol. 7: 152-158.
18. Follman DK, Fahrner RL. 2004. Factorial screening of antibody purification processes using three chromatography steps without protein A. J. Chromatogr. A 1024: 79-85.
19. Francisco JA, Campbell R, Iverson BL, Georgiou G. 1993. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl. Acad. Sci. U. S. A. 90: 10444-10448.
20. Francisco JA, Earhart CF, Georgiou G. 1992. Transport and anchoring of beta-lactamase to the external surface of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 89: 2713-2717.
21. Ghose S, Hubbard B, Cramer SM. 2006. Evaluation and comparison of alternatives to Protein A chromatography Mimetic and hydrophobic charge induction chromatographic stationary phases. J. Chromatogr. A 1122: 144-152
22. Hassan S, Van Dolleweerd CJ, Ioakeimidis F, Keshavarz-Moore E, Ma JK. 2008. Considerations for extraction of monoclonal antibodies targeted to different subcellular compartments in transgenic tobacco plants. Plant Biotechnol. J. 6: 733-748.
23. Hober S, Nord K, Linhult M. 2007. Protein A chromatography for antibody purification. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848: 40-47.
24. Hood EE, Woodard SL, Horn ME. 2002. Monoclonal antibody manufacturing in transgenic plants-myths and realities. Curr. Opin. Biotechnol. 13: 630-635.
25. Katsos NE, Labrou NE, Clonis YD. 2004. Interaction of L-glutamate oxidase with triazine dyes: selection of ligands for affinity chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 807: 277-285.
26. Ko K, Koprowski H. 2005. Plant biopharming of monoclonal antibodies. Virus Res. 111: 93-100.
27. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. 2004. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res. Hum. Retroviruses 20: 755-762.
28. Labrou NE. 2003. Design and selection of ligands for affinity chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 790: 67-78.
29. Labrou NE, Clonis YD. 1995. Biomimetic dye affinity chromatography for the purification of bovine heart-lactate dehydrogenase. J. Chromatogr. A 718: 35-44.
30. Labrou NE, Eliopoulos E, Clonis YD. 1999. Molecular modeling for the design of a biomimetic chimeric ligand. Application to the purifi- cation of bovine heart L-lactate dehydrogenase. Biotechnol. Bioeng. 63: 322-332.
31. Langer E, Ranck J. 2006. Capacity bottleneck squeezed by downstream processes. Bioprocess Int. 4: 14-18.
32. Li R, Dowd V, Stewart DJ, Burton SJ, Lowe CR. 1998. Design, synthesis, and application of a protein A mimetic. Nat. Biotechnol. 16: 190-195.
33. Lienard D, Sourrouille C, Gomord V, Faye L. 2007. Pharming and transgenic plants. Biotechnol. Annu. Rev. 13: 115-147.
34. Livingston AG, Chase HA. 1989. Preparation and characterization of adsorbents for use in high-performance liquid affinity chromatography. J. Chromatogr. A 481: 159-174.
35. Lowe CR. 2001. Combinatorial approaches to affinity chromatography. Curr. Opin. Chem. Biol. 5: 248-256.
36. Lu Z, Murray KS, Van CV, LaVallie ER, Stahl ML, McCoy JM. 1995. Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology (NY) 13: 366-372.
37. Ma JK, Barros E, Bock R, Christou P, Dale PJ, Dix PJ, Fischer R, Irwin J, Mahoney R, Pezzotti M, Schillberg S, Sparrow P, Stoger E, Twyman RM. 2005. Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep. 6: 593-599.
38. Ma JK, Drake PM, Christou P. 2003. The production of recombinant pharmaceutical proteins in plants. Nat. Rev. Genet. 4: 794-805.
39. Mazitsos CF, Rigden DJ, Tsoungas PG, Clonis YD. 2002. Galactosylmimodye ligands for Pseudomonas fluorescens beta-galactose dehydrogenase. Eur. J. Biochem. 269: 5391-5405.
40. Melissis SC, Rigden DJ, Clonis YD. 2001. New family of glutathionylbiomimetic ligands for affinity chromatography of glutathione- recognising enzymes. J. Chromatogr. A 917: 29-42.
41. Munier R. 1953. Separation of alkaloids from their N-oxides by paper chromatography. Bull. Soc. Chim. Biol. (Paris) 35: 1225-1231.
42. Peeters K, De Wilde C, De Jaeger G, Angenon G, Depicker A. 2001. Production of antibodies and antibody fragments in plants. Vaccine 19: 2756-2761.
43. Philippe B, Brion JP, Macq AF, Octave JN. 1993. A new monoclonal antibody against the anionic domain of the amyloid precursor protein of Alzheimer's disease. Neuroreport 5: 289-292.
44. Platis D, Drossard J, Fischer R, Ma J-KC, Labrou NE. 2008. New downstream processing strategy for the purification of monoclonal antibodies from transgenic tobacco plants. J. Chromatogr. A 1211: 80-89.
45. Platis D, Labrou NE. 2006. Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract. J. Chromatogr. A 1128: 114-124.
46. Platis D, Labrou NE. 2008. Affinity chromatography for the Purification of Therapeutic Proteins from Transgenic Maize using Immobilized Histamine. J. Sep. Sci. 31: 636-645.
47. Platis D, Sotriffer CA, Clonis Y, Labrou NE. 2006. Lock-and-key motif as a concept for designing affinity adsorbents for protein purification. J. Chromatogr. A 1128: 138-151.
48. Ramessar K, Rademacher T, Sack M, Stadlmann J, Platis D, Stiegler G, Labrou N,Altmann F, Ma J,Stoger E, Capell T,Christou P. 2008. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc. Natl. Acad. Sci. U. S. A. 105: 3727-3732.
49. Roque AC, Lowe CR, Taipa MA. 2004a. Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog. 20: 639-654.
50. Roque AC, Taipa MA, Lowe CR. 2004b. A new method for the screening of solid-phase combinatorial libraries for affinity chromatography. J. Mol. Recognit. 17: 262-267.
51. Scott JK, Smith GP. 1990. Searching for peptide ligands with an epitope library. Science 249: 386-390.
52. Shimizu F, Kist M, Vogt A. 1978a. Differences in the isoelectric focussing pattern of antibodies to human serum albumin eluted from an immunoadsorbent (HSA-sepharose) with thiocyanate ions. Res. Exp. Med. (Berl) 172: 231-238.
53. Shimizu F, Mossmann H, Himmelspach K,Takamiya H, Vogt A. 1978b. Separation of anti-dinitrophenyl antibodies according to affinity by fractionated elution from immunoadsorbent using thiocyanate. Res. Exp. Med. (Berl) 173: 165-171.
54. Shukla AA, Hubbard B, Tressel T,Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies-application of platform approaches. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848: 28-39.
55. Sibille P, Ternynck T, Nato F,Buttin G, Strosberg D,Avrameas A. 1997. Mimotopes of polyreactive anti-DNA antibodies identified using phage-display peptide libraries. Eur. J. Immunol. 27: 1221-1228.
56. Singleton VL, Rossi Jr JA. 1965. Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am. J. Enol. Vitic. 16: 144-158.
57. Stiegler G, Katinger H. 2003. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J. Antimicrob. Chemother. 51: 757-759.
58. Stiegler G, Kunert R, Purtscher M,Wolbank S, Voglauer R,Steindl F, Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17: 1757-1765. (Pubitemid 34114213)
59. Stockwin LH, Holmes S. 2003. The role of therapeutic antibodies in drug discovery. Biochem. Soc. Trans. 31: 433-436.
60. Stoger E, Ma JK, Fischer R, Christou P. 2005. Sowing the seeds of success: pharmaceutical proteins from plants. Curr. Opin. Biotechnol. 16: 167-173.
61. Stoger E, Sack M, Fischer R,Christou P. 2002. Plantibodies: applications, advantages and bottlenecks. Curr. Opin. Biotechnol. 13: 161-166.
62. Teng SF, Sproule K, Hussain A,Lowe CR. 1999. A strategy for the generation of biomimetic ligands for affinity chromatography. Combinatorial synthesis and biological evaluation of an IgG binding ligand. J. Mol. Recognit. 12: 67-75.
63. Terman DS. 1985. Protein A and staphylococcal products in neoplastic disease. Crit. Rev. Oncol. Hematol. 4: 103-124.
64. Terman DS, Bertram JH. 1985. Antitumor effects of immobilized protein A and staphylococcal products: linkage between toxicity and efficacy, and identification of potential tumoricidal reagents. Eur. J. Cancer Clin. Oncol. 21: 1115-1122.
65. Thomsen R, Christensen MH. 2006. MolDock: a new technique for highaccuracy molecular docking. J. Med. Chem. 49: 3315-3321.
66. Twyman RM, Stoger E, Schillberg S,Christou P, Fischer R. 2003. Molecular farming in plants: host systems and expression technology. Trends Biotechnol. 21: 570-578.
67. Vancan S, Miranda EA, Bueno SMA. 2002. IMAC of human IgG: studies with IDA-immobilized copper, nickel, zinc, and cobalt ions and different buffer systems. Process Biochem. 37: 573-579.
68. Walsh G. 2004. Second-generation biopharmaceuticals. Eur. J. Pharm. Biopharm. 58: 185-196.
69. Zwick MB, Jensen R, Church S,Wang M, Stiegler G,Kunert R, Katinger H,Burton DR. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79: 1252-1261.